AUM will use the funds generated to advance clinical development of its portfolio and immediately launch two Phase II programs for MNK and TRK inhibitors.
Vishal Doshi, CEO and co-founder of AUM Biosciences, describes the impetus from top private equity firms: Our talented founders and leaders are proud to have the trust and support of Everlife and SPRIM Global Investments. These proven investors share our enthusiasm for developing new treatments for patients with unmet needs. “
Earlier this year, AUM Biosciences, in collaboration with Newsoara Biopharma, will collaborate with Newsoara Biopharma on a five-year transformation to co-develop and co-discover next-generation cancer treatments (up to US $ 135 million in corporate value) in 2020. Announced a strategic partnership. Diversify and expand your medical portfolio.
Dr. Arjun Oberoi, Executive Chairman of Everlife, describes the role this collaboration can play in expanding Everlife’s clinical presence: This collaboration will help us position us more strongly throughout the oncology ecosystem, providing immediate access to AUM’s network of laboratories and networks of Southeast Asian partners. “
AUM Biosciences Ends $ 27 Million Series-Everlife, SGI Top Investors, Health News, ET Health World Financing Round
Source link AUM Biosciences Ends $ 27 Million Series-Everlife, SGI Top Investors, Health News, ET Health World Financing Round